Lightbridge Corporation (LTBR)
NASDAQ: LTBR · Real-Time Price · USD
8.34
+0.38 (4.77%)
At close: Apr 23, 2025, 4:00 PM
8.33
-0.01 (-0.12%)
After-hours: Apr 23, 2025, 7:28 PM EDT
Company Description
Lightbridge Corporation, together with its subsidiaries, engages in research, developing, and commercializing nuclear fuel.
It develops nuclear fuel for water-cooled reactors; and metallic fuels under the Lightbridge Fuel. Lightbridge Corporation is headquartered in Reston, Virginia.
Lightbridge Corporation
Country | United States |
Founded | 1992 |
Industry | Electrical Equipment & Parts |
Sector | Industrials |
Employees | 10 |
CEO | Seth Grae |
Contact Details
Address: 11710 Plaza America Drive, Suite 2000 Reston, Virginia 20190 United States | |
Phone | 571 730 1200 |
Website | ltbridge.com |
Stock Details
Ticker Symbol | LTBR |
Exchange | NASDAQ |
Stock Type | Common Stock |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001084554 |
CUSIP Number | 53224K302 |
ISIN Number | US53224K3023 |
Employer ID | 91-1975651 |
SIC Code | 8742 |
Key Executives
Name | Position |
---|---|
Seth Grae | President, Chief Executive Officer and Chairman of the Board |
Lawrence Goldman CPA | Chief Financial Officer and Corporate Secretary |
Dr. Andrey Mushakov | Executive Vice President of Nuclear Operations |
Joel B. Grae | Co-Founder |
Matthew Abenante | Director of Investor Relations |
Darla M. Bond | Human Resources Manager |
Robert H. Ihde | Senior Vice President of Nuclear Technology and Member of Technical Advisory Board |
Sherrie Holloway | Controller |
Linda Joan Zwobota CIA, CPA | Part-Time Consultant |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 28, 2025 | 144 | Filing |
Mar 24, 2025 | ARS | Filing |
Mar 24, 2025 | DEF 14A | Other definitive proxy statements |
Mar 21, 2025 | 8-K | Current Report |
Mar 20, 2025 | 144 | Filing |
Mar 13, 2025 | PRE 14A | Other preliminary proxy statements |
Mar 3, 2025 | 10-K | Annual Report |
Mar 3, 2025 | 8-K | Current Report |
Feb 26, 2025 | 8-K | Current Report |
Feb 13, 2025 | 144/A | Filing |